Awards
The Sunday Times’ Hundred Tech “Ones to Watch”
May 2026, The Times website – read more (Behind paywall)
Most Significant Contribution to the Mediscience Sector Award
June 2024, European Mediscience Awards website – read more
Primary R&D Company – ON Awards
April 2024, One Nucleus Annual Awards website – read more
In The News
Investors wake up to the merits of sleep biotech
6 June 2026
Financial Times
View story (Behind paywall)
How to profit from an ageing population
26 May 2026
MoneyWeek
View story
Oxford’s Smart Ageing Summit reveals new breakthroughs in longevity science and gives a first look at two new biotech pioneers.
21 May 2026
UK Business News
View story
MRC invests in experimental medicine dementia studies
19 December 2025
UK Research and Innovation (UKRI)
View story
Can a Good Night’s Sleep Help Avoid Alzheimer’s?
24 November 2025
Bloomberg
View story
21 UK biotech companies you should know about
24 April 2025
Labiotech
View story
AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer
AstronauTx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other neurological disorders by improving sleep architecture, announces the appointments of Dr. Michelle Mellion as Chief Medical Officer (CMO) and Deb Gouveia as Vice President, Clinical Operations and Development Strategy.
AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board
Seasoned executive with extensive board experience across US and European biotechnology companies Brings extensive operational, strategic and transactional expertise as AstronauTx advances its innovative pipeline targeting improvements in sleep architecture to treat neurodegenerative diseases London, UK, 7 January 2026 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other neurological […]
AstronauTx appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team
London UK, 1 October 2024 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders, today announces the appointment of Dr Jane Rhodes, PhD, MBA, as Chief Executive Officer (CEO) and member of the Board, and Magnus Ivarsson as Chief Translation and Early Development Officer.
AstronauTx closes £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease
London UK, 9 October 2023 – AstronauTx Ltd. (“AstronauTx”), a biotech company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders, today announced the completion of a £48 million ($61 million) Series A financing.
Saniona enters into collaboration agreement with AstronauTx in Alzheimer’s disease
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels, today announced a new research collaboration with AstronauTx in Alzheimer’s disease. Saniona may receive up to SEK 1.9 billion ($177 million) in milestone payments as well as royalties on worldwide net sales of resulting products under the collaboration.